secwatch.observer — SEC 8-K summary
======================================

Issuer:     Renalytix plc (RNLXY)
CIK:        0001811115
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0000950170-23-047260
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renalytix appoints Howard Doran as Chief Business Officer to lead KidneyIntelX sales
--------------------------------------------------------------------------------

- Howard Doran appointed Chief Business Officer effective Sept 1, 2023, to lead KidneyIntelX global sales.
- Doran brings 30+ yrs diagnostics exp; served as CEO of LipoScience (acquired by LabCorp) and President of Hologic Global Diagnostics.
- Annual base salary of $300,000; target bonus 60% of base; options for 300,000 ordinary shares with 3-yr vesting and 1-yr cliff.
- Renalytix commercializes FDA-approved AI prognostic blood test for type 2 diabetes and chronic kidney disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023047260/0000950170-23-047260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811115/000095017023047260/rnlx-20230901.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-047260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer